IGF2BP2-AS1
Putative uncharacterized protein IGF2BP2-AS1
Also known as: IFAS1_HUMAN
Protein identityUniProt · HPA
- UniProt accession
- Q96M15
- Gene
- IGF2BP2-AS1
- Canonical length
- 143 aa
OverviewNCBI Gene
No narrative summary is available for IGF2BP2-AS1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
143 residues, UniProt reviewed canonical sequence.
>Q96M15|IGF2BP2-AS1
1 MATPLDNCLR PFPDPMVKVT AETKKISEVS SYVSANNKKN SFWGSGLLYP VALLRCQDCW
61 AGHQTHVLSK EFTSYFSSGA GREAQHQPSA VLGSLIWLRR VYLLRAMVVH GGSQPCQRWL
121 VIRMEVGGHP SFPGHAWLTF HLNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IGF2BP2-AS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IGF2BP2-AS1 as an antibody target. Whether an autoantibody or antibody against IGF2BP2-AS1 could matter depends on whether native IGF2BP2-AS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IGF2BP2-AS1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IGF2BP2-AS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...